Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HDM3010
- Development stage
- Phase 3
- Lead developer
- Hangzhou Zhongmei Huadong Pharmaceutical
- Administration
- Topical
01
Overview
HDM3010 is an investigational drug developed by Hangzhou Zhongmei Huadong Pharmaceutical and Huadong Pharmaceutical (Xi'an) Bohua Pharmaceutical. It is being studied as a topical therapy for dermatological conditions, specifically prurigo nodularis and vitiligo. The precise mechanism of action for HDM3010 has not been disclosed publicly, and it is described as having an unknown or novel mechanism. Clinical trials are ongoing in China, including a multicenter, randomized, double-blind, placebo-controlled phase III study in patients with vitiligo and a phase I/II study evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in adults with prurigo nodularis[2][4]. The drug has not received regulatory approval in any country.
- Brand names
- HDM3010HDM-3010HDM 3010
- Other names
- HDM3010HDM-3010HDM 3010
Beyond the preview
Go deeper on HDM3010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HDM3010.